New Building Blocks for May 2022_ChemScene -코아사이언스

안녕하세요!

Building Blocks & Bioactive Molecules 전문제조사 ChemScene 수입/공급 업체 코아사이언스 입니다.

 

자세한 상품 정보 및 관련 문의는 전화 02-858-0328 또는 info@coresciences.co.kr로 문의주시기 바랍니다.

감사합니다!

Poly (ADP-ribose) polymerase (PARP) is a family of enzymes containing 17 members, of which 15 have been shown to catalyze the transfer ADP-ribose to target proteins[1]. PARP1 and PARP2 play important roles in DNA repair, making them an attractive target for oncology. PARP1 has been considered a new drug target based on the synthetic lethality strategy in BRCA1/2-mutated cancer patients. Currently, there are four FDA-approved PARP inhibitors in the market (Olaparib, Rucaparib, Niraparib, Talazoparib) for the treatment of recurrent ovarian cancer and breast cancer[2-7]. At the AACR annual meeting 2022, AstraZeneca disclosed the clinical trial results of AZD5305. The results show that AZD5305 is a highly selective PARP1 inhibitor with good safety and clinical activity in a variety of cancers[8-9].

 

A series of building blocks will be used as molecular fragments in the design of PARP inhibitors

[1] Journal of Medicinal Chemistry (2020), 63, 23, 14151-14183.
[2] European Journal of Medicinal Chemistry (2020), 204, 112635.
[3] Journal of Medicinal Chemistry (2020), 63, 24, 15541-15563.
[4] European Journal of Medicinal Chemistry (2019), 165, 198-215.
[5] Journal of Medicinal Chemistry (2015), 58, 21, 8683-8693.
[6] Journal of Medicinal Chemistry (2017), 60, 4, 1262-1271.
[7] Nature (2020), 579, 598-602.
[8] WO2021013735A1.
[9] WO2021260092A1.

 

 

코아사이언스 coresciences Chemscene Korea 한국 대리점 Korea distributor pharmaceutical ingredients natural compounds standards